アズノール^<【○!R】>STの感冒予防効果 : 鼻腔内投与と口腔内投与の比較 A Clinical Study of Azunol^<【○!R】> ST for Common Cold : A Comparision of Effects between Administration in the Oral and Nasal Cavities
Azunol® ST contains 5mg water soluble Azunol in one tablet, and in this study Azunol® ST was administered into the nasal cavity of 67 patient (nasal group) and into the labiogingival region of the upper jaw in 47 patients (oral group) with common cold in the early stage and the effects were compared to non-administration in 111 patients (control group). In all patients in the nasal and oral groups, one tablet was given before bed. The following results were obtained:<br>1) The rate of desease of common cold did not significantly differ among the three groups. (x<sup>2</sup> test)<br>2) In the nasal and oral groups, the rate of preventing progression was higher than in the control group (P<0.05). (nasal group 90±22%, oral group 91±20%, control group 76±38%)<br>3) The affected period was significantly shorter in the nasal group than in the control group. (P<0.05), but there was no significant difference between the nasal and oral groups or between the oral and control groups (The period of affection: nasal group 4.29±3.53 days, oral group 6.45±5.84 days, control group 8.06±6.11 days)<br>4) When the initial symptom was epipharyngalgia, the administration of Azunol® ST in the nasal cavity completely prevented (100%) the progression of symptoms, however, the rate of preventing progression was not significantly different between the oral (61%) and control groups (70%).
耳鼻咽喉科臨床 94(9), 849-853, 2001-09-01